Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers.
about
Surgery in the era of the 'omics revolutionReactivity against microsatellite instability-induced frameshift mutations in patients with inflammatory bowel disease.The mutational profile and infiltration pattern of murine MLH1-/- tumors: concurrences, disparities and cell line establishment for functional analysis.Lung tumor exome files with T-cell receptor recombinations: a mouse model of T-cell infiltrates reflecting mutation burdens.Microsatellite Instability and Promoter Hypermethylation of DNA repair genes in Hematologic Malignancies: a forthcoming direction toward diagnostics.Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: Evidence for high level B-cell infiltrates in breast cancer.Microsatellite instability in hematological malignancies: Hypermutation vs. immune control-who is challenging who?Cytoskeleton and ECM tumor mutant peptides: Increased protease sensitivities and potential consequences for the HLA class I mutant epitope reservoir.Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy.Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.Cellular vaccination of MLH1-/- mice - an immunotherapeutic proof of concept study.T cell receptor gene recombinations in human tumor specimen exome files: detection of T cell receptor-β VDJ recombinations associates with a favorable oncologic outcome for bladder cancer.PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours.
P2860
Q26852061-7D441B26-A0C5-415E-8C87-772758216340Q34827304-C20C06EE-6DDF-4927-A899-D9F62154DAC2Q37619794-8C62D5C3-C478-47B0-A4E7-9E893FF5F2F2Q38626084-D5B99C70-8330-4E70-87E8-4E4E04528F8EQ39448190-E26B9815-C4D3-499E-BDD6-9D1BEB323BAEQ40372850-02CBD006-249E-44E3-8CFF-7C07BD2C98EBQ42937984-DD6DE39D-F5DF-40B9-9F01-70FBEC039C0BQ47630972-C3B91F02-A8F7-4E2C-96BE-F35E38594778Q47797670-5A6A2CB6-1E4E-403E-BF97-3AEFCD491332Q49551908-30B550C4-6A4B-4148-9854-0BD4772699B8Q50423289-41669C05-05B4-4BBF-A799-FECD2CB2F8C7Q51249259-8F8103BD-214E-48F6-AB06-206A39179A5FQ52723008-C38F1F71-8AF2-4E84-8A18-DAF48AA79E99
P2860
Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Frameshift-derived neoantigens ...... r treating MSI+ blood cancers.
@en
Frameshift-derived neoantigens ...... r treating MSI+ blood cancers.
@nl
type
label
Frameshift-derived neoantigens ...... r treating MSI+ blood cancers.
@en
Frameshift-derived neoantigens ...... r treating MSI+ blood cancers.
@nl
prefLabel
Frameshift-derived neoantigens ...... r treating MSI+ blood cancers.
@en
Frameshift-derived neoantigens ...... r treating MSI+ blood cancers.
@nl
P2093
P1476
Frameshift-derived neoantigens ...... or treating MSI+ blood cancers
@en
P2093
Claudia Maletzki
Fabian Schmidt
Michael Linnebacher
Michael Schmitt
P304
P356
10.1016/J.EJCA.2013.02.035
P50
P577
2013-04-02T00:00:00Z